Company: ACBM
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001640334-25-001347
Chunk: 1

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-08-05
Form: 10-Q
Item: Item 1
Chunk 1
---
13,614   9,086   22,548   19,384 Total operating expenses  13,614   9,086   22,548   19,384                  Loss from operations  (13,614)  (9,086)  (22,548)  (19,384)                 Other expense                Interest expense - related parties  1,948   1,057   3,315   2,011 Total other expenses  1,948   1,057   3,315   2,011                  Loss before income tax expense  (15,562)  (10,143)  (25,863)  (21,395)Income tax expense  -   -   -   - Net loss $(15,562) $(10,143) $(25,863) $(21,395)                 Basic and diluted Loss per share of common stock $(0.00) $(0.00) $(0.00) $(0.00)                 Weighted average number of shares of common stock outstanding  60,042,000   60,042,000   60,042,000   60,042,000 

The accompanying notes are an integral part of these unaudited financial statements.

 5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Deficit

(Unaudited)

For the Three and Six months ended June 30, 2025

          Additional    Total   Preferred Stock  Common Stock   Paid in   Accumulated  Stockholders'     Shares    Amount    Shares    Amount    Capital    Deficit   Deficit                       Balance, December 31, 2024  -  $-   60,042,000  $60,042  $32,302,781  $(32,657,795) $(294,972)                             Imputed interest on related party loans  -   -   -   -   1,367   -   1,367 Net loss  -